MedAssets valuation is exceptionally attractive, says RW Baird Baird believes the valuation of MedAssets is exceptionally attractive and raised its price target to $25 from $24. The firm cited recent contract wins, expansions, and believes it will hit its above Street Q4 guidance. Shares are Outperform rated.
News For MDAS From The Last 14 Days
Check below for free stories on MDAS the last two weeks.
MedAssets upgraded to Outperform from Market Perform at Leerink Leerink upgraded MedAssets to Outperform citing the pullback in shares since the Q2 results, the potential for improving volumes in Q3 and the company's total portfolio approach. The firm has a $26 price target for shares.